Freeline Therapeutics Holdings PLC reports results for the quarter ended in December - Earnings Summary

Freeline Therapeutics Holdings

04/04/2023 13:00

* Freeline Therapeutics Holdings PLC  FRLN.OQ  reported a
quarterly adjusted loss of 58 cents​​ per share for the quarter
ended in December. The mean expectation of five analysts for the
quarter was for a loss of 28 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Freeline Therapeutics Holdings PLC's reported EPS for the
quarter was a loss of 58 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Freeline Therapeutics Holdings PLC shares had risen
by 3.3% this
quarter and lost 1.1% so far this year.
    * The company reported a quarterly loss of $37.89 million.
    * Wall Street's median 12-month price target for Freeline
Therapeutics Holdings PLC is $3.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
April 4 at 12:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.28          -0.58          Missed
 Sep. 30 2022      -0.44          -0.20          Beat
 Jun. 30 2022      -0.51          -0.32          Beat
 Mar. 31 2022      -0.60          -0.63          Missed